Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery
- 1 November 2000
- journal article
- Published by Elsevier in Value in Health
- Vol. 3 (6) , 397-406
- https://doi.org/10.1046/j.1524-4733.2000.36005.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip ReplacementValue in Health, 1999
- Deep-vein thrombosisThe Lancet, 1999
- Economic Evaluation of Desirudin vs Heparin in Deep Vein Thrombosis Prevention after Hip Replacement SurgeryPharmacoEconomics, 1998
- Cost Effectiveness of a Low-Molecular-Weight Heparin in Prolonged Prophylaxis Against Deep Vein Thrombosis After Total Hip ReplacementPharmacoEconomics, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparinBritish Journal of Surgery, 1996
- Thromboprophylaxis and death after total hip replacementThe Journal of Bone and Joint Surgery. British volume, 1996
- Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at HomeNew England Journal of Medicine, 1996
- Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgeryBritish Journal of Surgery, 1994
- Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.BMJ, 1992